跳至主要内容
临床试验/NCT05085925
NCT05085925已完成不适用

Randomized Intervention Study of Mindfulness-Based Stress-Reduction to Improve the Quality of Life and Immune Regulation in Patients With Crohn's Disease

Soroka University Medical Center1 个研究点 分布在 1 个国家目标入组 142 人开始时间: 2018年6月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
142
试验地点
1
主要终点
Change in Crohn's disease specific health-related quality of life

研究概览

简要总结

A randomized controlled study which aims to improve the quality of life of Crohn's disease adult patients suffering from mild to moderate level of symptoms. Patients will be randomized to Intervention or Wait-List groups and will undergo eight Cognitive Behavioral and Mindfulness, one on one, sessions with a social worker via SkypeTM. The Intervention group will receive intervention upon recruitment while the Wait-List group will receive the same intervention after 3 months. Clinical, biological and psycho-social data will be collected at four time points over the 12-months of the study.

详细描述

  1. Overall objectives:

  2. Primary outcome: To determine whether mindfulness-based stress reduction will lead to a better health-related quality-of-life by use of three questionnaires:

• the Crohn's disease specific SIBDQ (Short Inflammatory Bowel Disease Questionnaire, with mean score and 4 subscales: bowel, systemic, social, emotional)

  • SF-12 (MOS Short-Form-12) which is derived from the generic SF-36 used in our previous research (SF-36 measures a Physical Health Summary Score comprised of physical functioning, role-physical, bodily pain and general health, and a Mental Health Summary Score comprised of vitality, role-emotional, social functioning and mental health).
  • EQ-5D (EuroQol questionnaire, for calculation of utility weights)
  1. Secondary outcomes: improvement in mindfulness (FMI, Freiburg Mindfulness Inventory); reduction of stress, anxiety and depression (BSI - Brief Symptom Inventory, GSI - General Severity Index stress measure, MSPSS- Multidimensional Scale of Perceived Social Support, PSS-4 Perceived Stress Scale, LEQ- life events questionnaire); better satisfaction with life (SWLS, Satisfaction with Life Scale); improved family function (FAD, Family Assessment Device); pain reduction (HBI, Harvey-Bradshaw Index of activity of Crohn's disease); less fatigue (FACIT Fatigue Scale); better coping with disease (COPE: Brief Cope Inventory - Brief Coping Operations Preference Enquiry); better performance at work (WPAI, Work Productivity and Activity Impairment) and cost estimation. Significant changes in the scores of these questionnaires, based on our current work comparing P-HBI remission versus active disease, are the following (all are given in points, except WPAI is percent): SIBDQ 6, SWLS 5, FAD 0.15, COPE dysfunctional 2.5, COPE emotion-focused 0.7, COPE problem-focused 0.6, WPAI time missed 14, WPAI percent impairment 29, WPAI work impairment 28, WPAI activity impairment 30, GSI 0.6, BSI anxiety 0.6, BSI depression 0.6. We did not use the SF-12, EQ-5D, MSPSS, PSS-4 and the FACIT Fatigue Scale in our previous research and will look at reports in the literature and our newly acquired data to determine what are significant improvements.

  2. Before and at the end of each intervention session a short assessment of patient's subjective units of distress (SUDS) will be done, as per Wolpe, Joseph (1969), The Practice of Behavior Therapy, New York: Pergamon Press, and the 4 question Short-Form Perceived Stress Scale, as per Warttig et al, J Health Psychology 2013;18:1617-28.

  3. Correlations of psychological measures with demography, economic status, HBI, immune regulation, telomere shortening, fMRI data, changes in composition of microbiota. Change in biophysical parameters as sleep physical activity & pulse rate.

  4. To determine whether the intervention is cost-saving or cost-effective, by prospective monitoring of resource use and indirect costs.

  5. To determine whether the intervention can be given effectively using telemedicine with Skype or alternative software.

  6. To study patient acceptability of the intervention, including recruitment and drop-out rate, and the adherence rate to home practice of the stress reduction measure taught.

  7. Expected outcomes

  8. Reduced HBI, improvement of all the psychological measures including both quality-of-life and satisfaction with life, less stress, less fatigue, more use of adaptive coping strategies, with no clear improvements in the control group. Improvement in biophysical parameters as sleep physical activity & pulse rate.

  9. The research will identify the best form of delivering the interventional therapy and if it is cost-saving or cost-effective.

  10. Confirmation of the reliability of measurements of modification of immune regulation mechanisms and telomere length, grey matter thickness and composition of the microbiota.

  11. Glucocorticoid resistance and related laboratory determinations on patients' leukocytes will add to understanding the biological mechanisms associated with stress-induced pathogenic autoimmunity in the patients in a sex-dependent manner. This will add to our understanding the biological mechanisms associated with stress in Crohn's disease.

  12. Work plan and methodology

a. Patient recruitment i. Patients: 200 patients being treated at all the participating hospitals (Soroka Medical Center, Rambam Health Campus, Sheba Medical Center, Rabin Medical Center, Shaare Zedek Medical Center), which all have electronic records of large cohorts of patients with Crohn's disease and by advertising through patient support groups and institutions upon approval. The recruitment of patients will be offered in all the hospitals. Preference will be given to patients who have participated in the previous IIRN study and are now participating in the new IIRN studies proposed by the other hospitals, and those patients in higher risk groups (poorer men, female gender, etc.).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Willingness to participate and commit to a one-year process
  • •Age 18-75 years
  • •Hebrew-speaking
  • •Proven diagnosis of mild/moderate Crohn's disease
  • •At least 3 months post-diagnosis

排除标准

  • •Crohn's disease that is severe (HBI >16) or in remission (HBI<5)
  • •Ulcerative colitis, IBD unclassified
  • •Planned surgery or surgery in last 6 months
  • •Psychiatric disease
  • •Psychotropic medication
  • •Alcohol or drug dependency
  • •Pregnancy
  • •Significant or poorly controlled comorbidity

研究组 & 干预措施

Cognitive behavioral mindfulness intervention at entry

Experimental

Cognitive behavioral mindfulness intervention at entry

干预措施: Cognitive behavioral mindfulness intervention (Behavioral)

Cognitive behavioral mindfulness intervention after 3 months

Active Comparator

Cognitive behavioral mindfulness intervention after 3 months of wait list

干预措施: Cognitive behavioral mindfulness intervention after 3-month wait list (Behavioral)

结局指标

主要结局

Change in Crohn's disease specific health-related quality of life

时间窗: Measured at baseline, 3-months, 6-months, 12-months

Measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Range: 10-70; Higher score indicates better quality of life

Change in general health profile

时间窗: Measured at baseline, 3-months, 6-months, 12-months

Measured by the Short Form-12 (SF-12); 0-100; Higher scores indicate better quality of life

Change in utility weights

时间窗: Measured at baseline, 3-months, 6-months, 12-months

Measured by the EuroQoL (EQ-5D-3L); 0-1; Higher scores indicate higher and better utility weights

次要结局

  • Social support(Measured at baseline, 3-months, 6-months, 12-months)
  • Stress, anxiety and depression(Measured at baseline, 3-months, 6-months, 12-months)
  • Perceived stress(Measured at baseline, 3-months, 6-months, 12-months)
  • Satisfaction with life(Measured at baseline, 3-months, 6-months, 12-months)
  • Fatigue(Measured at baseline, 3-months, 6-months, 12-months)
  • Pain reduction(Measured at baseline, 3-months, 6-months, 12-months)
  • Coping with disease(Measured at baseline, 3-months, 6-months, 12-months)
  • Performance at work(Measured at baseline, 3-months, 6-months, 12-months)
  • Resource utilization and healthcare costs(Measured at baseline, 3-months, 6-months, 12-months)
  • Mindfulness(Measured at baseline, 3-months, 6-months, 12-months)
  • Family Support(Measured at baseline, 3-months, 6-months, 12-months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr Doron Schwartz

Senior Physician, Department of Gastroenterology and Hepatology

Soroka University Medical Center

研究点 (1)

Loading locations...

相似试验

Mindfulness-Based Stress-Reduction in Patients With... | 临床试验